%0 Journal Article
%A Jung, Seungyoun
%A Allen, Naomi
%A Arslan, Alan A
%A Baglietto, Laura
%A Barricarte, Aurelio
%A Brinton, Louise A
%A Egleston, Brian L
%A Falk, Roni T
%A Fortner, Renée T
%A Helzlsouer, Kathy J
%A Gao, Yutang
%A Idahl, Annika
%A Kaaks, Rudolph
%A Krogh, Vittorio
%A Merritt, Melissa A
%A Lundin, Eva
%A Onland-Moret, N Charlotte
%A Rinaldi, Sabina
%A Schock, Helena
%A Shu, Xiao-Ou
%A Sluss, Patrick M
%A Staats, Paul N
%A Sacerdote, Carlotta
%A Travis, Ruth C
%A Tjønneland, Anne
%A Trichopoulou, Antonia
%A Tworoger, Shelley S
%A Visvanathan, Kala
%A Weiderpass, Elisabete
%A Zeleniuch-Jacquotte, Anne
%A Dorgan, Joanne F
%T Anti-Müllerian hormone and risk of ovarian cancer in nine cohorts.
%J International journal of cancer
%V 142
%N 2
%@ 0020-7136
%C Bognor Regis
%I Wiley-Liss
%M DKFZ-2018-00057
%P 262 - 270
%D 2018
%X Animal and experimental data suggest that anti-Müllerian hormone (AMH) serves as a marker of ovarian reserve and inhibits the growth of ovarian tumors. However, few epidemiologic studies have examined the association between AMH and ovarian cancer risk. We conducted a nested case-control study of 302 ovarian cancer cases and 336 matched controls from nine cohorts. Prediagnostic blood samples of premenopausal women were assayed for AMH using a picoAMH enzyme-linked immunosorbent assay. Odds ratios (ORs) and 95
%K Biomarkers (NLM Chemicals)
%K Anti-Mullerian Hormone (NLM Chemicals)
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:28921520
%2 pmc:PMC5749630
%R 10.1002/ijc.31058
%U https://inrepo02.dkfz.de/record/131758